PURE · XBRL financial data

PURE Bioscience financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (PURE's year ends in late July)

In thousands of dollars	Q1 FY24Oct 31, 2023	Q2 FY24Jan 31, 2024	Q3 FY24Apr 30, 2024	Q4 FY24Jul 31, 2024	Q1 FY25Oct 31, 2024	Q2 FY25Jan 31, 2025	Q3 FY25Apr 30, 2025	Q4 FY25Jul 31, 2025	Q1 FY26Oct 31, 2025	Q2 FY26Jan 31, 2026	Q3 FY26Apr 30, 2026	Q4 FY26Jul 31, 2026
Revenue	718	325	440	472*	555	391	489	763*	707	443	506	659*
Revenue from contracts with customers	722	326	441	474*	556	391	491	764*	708	444	506	660*
Cost of goods and services sold	280	149	183	199*	231	164	208	296*	258	206	237	291*
Gross profit	442	177	258	—	325	227	283	—	450	238	269	—
Research and development	80	76	77	69*	71	81	91	73*	86	74	79	93*
Selling, general and administrative	1,073	1,065	998	845*	881	871	776	731*	743	847	708	779*
General and administrative	—	—	—	—	—	844	743	—	—	789	653	—
Total operating expenses	1,153	1,141	1,075	974*	952	952	867	804*	829	921	787	872*
Operating income (loss)	(711)	(964)	(817)	(699)*	(627)	(725)	(584)	(336)*	(379)	(683)	(518)	(503)*
Interest expense	24	38	41	52*	62	70	78	89*	94	101	106	106*
Other income (expense)	—	—	1	(5)*	—	(3)	82	93*	9	(1)	0*	(1)*
Income tax expense (benefit)	—	—	—	year only	—	—	—	year only	—	—	—	year only
Net income (loss)	(735)	(1,002)	(857)	(756)*	(689)	(798)	(580)	(332)*	(464)	(785)	(624)	(610)*
Earnings per share, basic USD per share	(0.01)	(0.02)	(0.01)	(0.01)*	(0.01)	(0.01)	(0.01)	0.00*	0.00	(0.01)	(0.01)	0.00*
Earnings per share, diluted USD per share	(0.01)	(0.02)	(0.01)	(0.01)*	(0.01)	(0.01)	(0.01)	0.00*	0.00	(0.01)	(0.01)	0.00*
Weighted average shares, basic thousands of shares	111,856	111,856	111,856	111,856*	111,856	111,856	111,856	111,882*	111,886	111,886	110,833	131,037*
Weighted average shares, diluted thousands of shares	111,856	111,856	111,856	111,856*	111,856	111,856	111,856	111,882*	111,886	111,886	110,833	131,037*

Balance sheet

CSV

Fiscal quarters (PURE's year ends in late July)

In thousands of dollars	Q1 FY24Oct 31, 2023	Q2 FY24Jan 31, 2024	Q3 FY24Apr 30, 2024	Q4 FY24Jul 31, 2024	Q1 FY25Oct 31, 2024	Q2 FY25Jan 31, 2025	Q3 FY25Apr 30, 2025	Q4 FY25Jul 31, 2025	Q1 FY26Oct 31, 2025	Q2 FY26Jan 31, 2026	Q3 FY26Apr 30, 2026	Q4 FY26Jul 31, 2026
Cash and cash equivalents	1,440	557	442	349	346	202	540	334	434	198	983	569
Accounts receivable	347	171	234	298	371	180	287	474	389	252	242	334
Inventory	104	74	74	56	72	75	131	141	237	244	232	193
Total current assets	2,066	939	869	805	911	562	1,046	1,047	1,176	779	1,549	1,185
Property and equipment, net	184	147	51	13	13	12	11	11	10	9	9	8
Total assets	2,250	1,086	920	818	924	574	1,057	1,058	1,186	788	1,558	1,193
Accounts payable	652	409	506	601	718	700	799	784	879	767	719	820
Accrued liabilities	154	136	160	132	193	166	173	154	176	149	181	170
Total current liabilities	806	545	666	733	911	866	972	938	3,159	3,055	3,654	4,371
Total liabilities	2,633	2,407	3,066	3,682	4,420	4,841	5,871	6,174	6,732	7,061	7,397	7,592
Accumulated deficit	(133,980)	(134,982)	(135,839)	(136,595)	(137,284)	(138,082)	(138,662)	(138,994)	(139,458)	(140,243)	(140,867)	(141,477)
Total stockholders' equity	(383)	(1,321)	(2,146)	(2,864)	(3,496)	(4,267)	(4,814)	(5,116)	(5,546)	(6,273)	(5,839)	(6,399)
Total liabilities and equity	2,250	1,086	920	818	924	574	1,057	1,058	1,186	788	1,558	1,193
Common shares outstanding (cover page) thousands of shares	111,856	111,856	111,856	111,856	111,856	111,856	111,886	111,886	111,886	111,886	130,018	140,201

Cash flows

CSV

Fiscal quarters (PURE's year ends in late July)

In thousands of dollars	Q1 FY24Oct 31, 2023	Q2 FY24Jan 31, 2024	Q3 FY24Apr 30, 2024	Q4 FY24Jul 31, 2024	Q1 FY25Oct 31, 2024	Q2 FY25Jan 31, 2025	Q3 FY25Apr 30, 2025	Q4 FY25Jul 31, 2025	Q1 FY26Oct 31, 2025	Q2 FY26Jan 31, 2026	Q3 FY26Apr 30, 2026	Q4 FY26Jul 31, 2026
Net income (loss)	(735)	(1,002)	(857)	(756)*	(689)	(798)	(580)	(332)*	(464)	(785)	(624)	(610)*
Stock-based compensation	80	64*	32*	38*	57	27	33	30*	34	58	55	50*
Net cash from operating activities	(440)	(883)*	(615)*	(593)*	(503)	(544)*	(512)*	(456)*	(250)	(606)*	(468)*	(414)*
Net cash from financing activities	785	0*	500*	500*	500	400*	850*	250*	350	370*	1,253*	0*
Net change in cash	345	(883)*	(115)*	(93)*	(3)	(144)*	338*	(206)*	100	(236)*	785*	(414)*

Compare with peers

SIC 2890 and related industry codes, similar size; rows marked “added: same SIC” fill a short list. Each row is the latest quarter reported.

How peers are chosen

SIC 2890 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Fewer than three companies fall in that range, so the list adds same-SIC (2890) companies nearest in public float, each marked “added: same SIC”.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Pure Bioscience	569	659*	(414)*	140.2M	1.4 quarters	Q4 FY26 10-KJul 31, 2026
NEXT-ChemXadded: same SIC	22	not reported	(329)*	28.5M	0.1 quarters	Q2 FY25 10-QJun 30, 2025
Flexible Solutions Internationaladded: same SIC	7,198	7,610	5,313*	12.8M	—	Q2 FY26 10-QJun 30, 2026
Flotek Industriesadded: same SIC	4,402	99,367	(6,601)*	36.2M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Arqadded: same SIC	7,752	38,209	not reported	44.2M	—	Q3 FY26 10-QSep 30, 2026
ASP Isotopesadded: same SIC	219,596	5,123	(23,334)*	153.3M	10.9 quarters	Q2 FY26 10-QJun 30, 2026
Orionadded: same SIC	71,300	472,800	57,800*	56.5M	—	Q3 FY26 10-QSep 30, 2026
WD 40added: same SIC	70,607	176,780*	50,152*	13.4M	—	Q4 FY26 10-KAug 31, 2026
Element Solutionsadded: same SIC	224,900	995,300	159,200*	242.6M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.